Health
Definium's LSD therapy clears second late-stage anxiety trial
Definium stock rises on trial success
3 Sep 14 · 9d ago · 2 articles · 1 source · development 3 of 3
Share prices climbed following the announcement, continuing a year of strong investor enthusiasm for psychedelic-based therapies that has nearly tripled Definium's stock value since the start of 2026.
Definium Therapeutics Company developing DT120Robert Barrow CEO, Definium TherapeuticsGavin Clark-Gartner Analyst, Evercore ISI
The whole story articles the bright band is this development · numbered dots are the others · click one to jump
Sep 15Sep 16Sep 17Sep 18Sep 19Sep 20Sep 21Sep 22now · 8:51 AM ET
What was reported 1 claim about this development
-
first by Jerusalem Post, 9d ago · also Seeking Alpha
1 more headline
- Definium rises as LSD pill achieves primary goal in late-stage trial for anxiety Seeking Alpha · 9d ago
All 3 developments of Definium's LSD therapy clears second late-stage anxiety… →
NewswiresGoogle NewsReddit